Impact of Multidisciplinary Review of Drug Prescriptions on Patient Safety in a Residence for Dependent Elderly
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 4
- 主要终点
- Adverse Drug Events Geriatric Risk Score
研究概览
简要总结
The main objective of the study is to show that the multidisciplinary review of drug prescriptions changes the adverse drug event (ADE) geriatric risk score (according to Trivalle and Ducimetière 2013) for patients living in the Nîmes University Hospital Residence for Dependent Elderly.
详细描述
The secondary objectives of this study are to assess and compare the following criteria before and after multidisciplinary review of drug prescriptions for patients in the Nîmes University Hospital Residence for Dependent Elderly:
A. the number of patients with at least one potentially inappropriate drug prescribed
B. the number of hospitalizations
C. death rate
D. the number of falls per patient and the rate of fallers
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —(Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient (or his/her legal representative) must have given his/her informed and signed consent
- •The patient must be insured or beneficiary of a health insurance plan
- •The patient is available for 6 months of follow-up
- •The patient has resided at the Nîmes University Hospital Residence for Dependent Elderly for at least the past 6 months
排除标准
- •The patient is participating in another study
- •The patient is in an exclusion period determined by a previous study
- •The patient is under judicial protection
- •The patient (or his/her legal representative) refuses to sign the consent
- •It is impossible to correctly inform the patient (or his/her legal representative)
- •The patient has resided at the Nîmes University Hospital Residence for Dependent Elderly for less than 6 months
结局指标
主要结局
Adverse Drug Events Geriatric Risk Score
时间窗: change from Baseline to 6 months
according to Trivalle and Ducimetière 2013
次要结局
- The number of patients taking at least 1 potentially inappropriate drug according to Laroche criteria(During the proactive phase. Day 0.)
- Number of hospitalizations in the public sector (higher level care)(second observational phase (day 0 to month 6))
- Days of hospitalization in the public sector (higher level care)(second observational phase (day 0 to month 6))
- Mortality(second observational phase (day 0 to month 6))
- The number of falls per patient(second observational phase (day 0 to month 6))
- The percentage of patients who fell(second observational phase (day 0 to month 6))
- The Anatomical Therapeutic Chemical classification for each revised drug(during the proactive phase (day 0))
- The type of errors detected during drug review(during the proactive phase (day 0))
- The type of modification suggested during drug review(during the proactive phase (day 0))
- The acceptation rate for modifications suggested during drug review(during the proactive phase (day 0))
- Associated care costs (€)(second observational phase (day 0 to month 6))
